Generic Name: ado-trastuzumab emtansine (AY doe tras TOOZ ue mab em TAN seen)
Brand Name: Kadcyla
What is ado-trastuzumab emtansine?
Ado-trastuzumab emtansine may also be used for purposes not listed in this medication guide.
Do not use if you are pregnant. Use effective birth control, and tell your doctor if you become pregnant during treatment.
This medicine can harm your liver. Call your doctor at once if you have upper stomach pain, itching, loss of appetite, dark urine, clay-colored stools, or jaundice (yellowing of the skin or eyes).
Before taking this medicine
You should not use ado-trastuzumab emtansine if you are allergic to it.
Do not use ado-trastuzumab emtansine if you are pregnant. It could harm the unborn baby or cause birth defects. Use effective birth control to prevent pregnancy while you are using ado-trastuzumab emtansine and for at least 7 months after your last dose.
You may need to have a negative pregnancy test before starting this treatment. Tell your doctor if you become pregnant during treatment.
Tell your doctor if you have ever had:
bleeding or blood clotting disorder such as hemophilia; or
You should not breast-feed while using this medicine.
How is ado-trastuzumab emtansine given?
Ado-trastuzumab emtansine is given as an infusion into a vein. A healthcare provider will give you this injection.
Tell your caregivers if you feel any burning, pain, or swelling around the IV needle when ado-trastuzumab emtansine is injected.
Ado-trastuzumab emtansine is usually given once every 3 weeks until your body no longer responds to the medication. Your doctor will determine how long to treat you.
You may need frequent medical tests to be sure this medicine is not causing harmful effects. Your cancer treatments may be delayed based on the results.
What happens if I miss a dose?
Call your doctor for instructions if you miss an appointment for your ado-trastuzumab emtansine injection.
What happens if I overdose?
Since this medication is given by a healthcare professional in a medical setting, an overdose is unlikely to occur.
What should I avoid while taking ado-trastuzumab emtansine?
Avoid activities that may increase your risk of bleeding or injury. Use extra care to prevent bleeding while shaving or brushing your teeth.
ado-trastuzumab emtansine can pass into body fluids (urine, feces, vomit). For at least 48 hours after you receive a dose, avoid allowing your body fluids to come into contact with your hands or other surfaces. Caregivers should wear rubber gloves while cleaning up a patient's body fluids, handling contaminated trash or laundry or changing diapers. Wash hands before and after removing gloves. Wash soiled clothing and linens separately from other laundry.
Ado-trastuzumab emtansine side effects
Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Some side effects may occur during the injection. Tell your caregiver right away if you feel cold, light-headed, feverish or sweaty, or have chest tightness, rapid heartbeats, or trouble breathing.
Call your doctor at once if you have:
easy bruising, unusual bleeding, purple or red spots under your skin;
coughing up blood or vomit that looks like coffee grounds;
bloody or tarry stools;
chest pain, wheezing, dry cough, feeling short of breath;
unusual tiredness, feeling light-headed;
pale skin, cold hands and feet;
numbness, tingling, or burning pain in your hands or feet;
sudden numbness or weakness (especially on one side of the body), severe headache, slurred speech, balance problems;
liver problems--loss of appetite, stomach pain (upper right side), dark urine, jaundice (yellowing of the skin or eyes); or
Your cancer treatments may be delayed or permanently discontinued if you have certain side effects.
Common side effects may include:
easy bruising or bleeding (especially nosebleeds);
joint or muscle pain;
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Ado-trastuzumab emtansine dosing information
Usual Adult Dose for Breast Cancer:
3.6 mg/kg IV every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity
Maximum dose: 3.6 mg/kg IV every 3 weeks
-Administer the first infusion over 90 minutes. Subsequent infusions may be administered over 30 minutes as tolerated.
-Observe patients during and for at least 90 minutes following the initial dose for fever, chills, or other infusion-related reactions.
-Patients should have a HER2 positive tumor status confirmed prior to starting therapy.
-Do not substitute trastuzumab emtansine for or with trastuzumab.
-If a planned dose is delayed or missed, it should be administered as soon as possible; do not wait until the next planned cycle.
Use: As a single agent, for HER2-positive, metastatic breast cancer in patients who previously received trastuzumab and a taxane, separately or in combination; patients should have either:
-Received prior therapy for metastatic disease
-Developed disease recurrence during or within 6 months of completing adjuvant therapy
What other drugs will affect ado-trastuzumab emtansine?
Sometimes it is not safe to use certain medications at the same time. Some drugs can affect your blood levels of other drugs you take, which may increase side effects or make the medications less effective.
Other drugs may affect ado-trastuzumab emtansine, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.
Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.
Copyright 1996-2018 Cerner Multum, Inc. Version: 3.01.
More about ado-trastuzumab emtansine
- Ado-trastuzumab emtansine Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- En Español
- Drug class: HER2 inhibitors
- FDA Alerts (1)
Other brands: Kadcyla